Session 9

Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

Retrieved on: 
Friday, April 12, 2024
American Academy, Patient, AAN, Epilepsy, EEG, Therapy, Session 9, Ageing, Pharmaceutical industry

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.

Key Points: 
  • WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.
  • “This study underscores our ongoing dedication to enhancing the well-being of individuals battling epilepsy,” said Dan Barber, Aquestive President and Chief Executive Officer.
  • “When it comes to the treatment of seizure clusters in pediatric patients with epilepsy between ages two to five, we believe Libervant, as an oral alternative to existing device-based products, will be well-received by this patient population.”
    Poster Session 9: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Mechanisms, Pharmacokinetics, and Urgent Applications
    Presentation Time: Wednesday, April 17, from 8:00 AM - 9:00 AM.

Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting

Retrieved on: 
Friday, April 12, 2024
Real-World Evidence, Continuity, American Academy, University, FAAN, Parkinson's disease, Randomness, State university system, Abstract, Research, Spirometry, MDT, ALS, Movement disorder, AAN, Disease, MTPA, Control, Data mart, Boundless, Annual general meeting, ISR, University of Cincinnati, Session 9, Knowledge, Pharmaceutical industry

JERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024.

Key Points: 
  • JERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024.
  • The presentations will discuss four abstracts in Parkinson's disease (PD) and three in amyotrophic lateral sclerosis (ALS).
  • Data from the BouNDless subgroup analysis will be presented orally during a Scientific Platform Session at the meeting.
  • ; State University of New York Upstate Medical University)
    Poster Session 6 (#11-013): 8:00 – 9:00 a.m. MDT, April 16

Lytix Biopharma to present at the 'Frontiers in Cancer Immunotherapy 2023', invited by New York Academy of Sciences

Retrieved on: 
Wednesday, May 3, 2023
ICIS, Euronext Growth, Neoplasm, Session 9, Doctor of Philosophy, Cancer, Patient, Weill Cornell Medicine, NYAS, Tumor microenvironment, Pharmaceutical industry, Science

OSLO, Norway, May 3, 2023 /PRNewswire/ -- Lytix Biopharma - Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company - is pleased to announce that Dr Øystein Rekdal, CEO in Lytix Biopharma, today will give an oral presentation at the `Frontiers in Cancer Immunotherapy 2023' conference, which is taking place in New York, USA.

Key Points: 
  • OSLO, Norway, May 3, 2023 /PRNewswire/ -- Lytix Biopharma - Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company - is pleased to announce that Dr Øystein Rekdal, CEO in Lytix Biopharma, today will give an oral presentation at the `Frontiers in Cancer Immunotherapy 2023' conference, which is taking place in New York, USA.
  • Dr Rekdal has been invited by the New York Academy of Sciences to discuss how tumor-directed strategies enable superior immune-stimulation of `cold' non-infiltrated tumors, in a joint presentation with Lorenzo Galluzzi, PhD, Weill Cornell Medicine.
  • The presentation will be performed in Session 9: Cancer Vaccines, on May 3.
  • We are grateful for being invited by the New York Academy of Sciences (NYAS) to this conference and to present our clinical data confirming the strong pre-clinical evidence of our proposed solution to the problem of `cold' tumors in cancer immunotherapy", says Dr. Øystein Rekdal.